| P2093 | author name string | Yi Liu | |
| | Zhigang Li | |
| | Chao Gao | |
| | Lei Cui | |
| | Shuguang Liu | |
| | Weijing Li | |
| | Xiaoxi Zhao | |
| | Minyuan Wu | |
| | Ruidong Zhang | |
| P2860 | cites work | Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. | Q31012437 |
| | Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. | Q31099184 |
| | Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse | Q33798890 |
| | Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. | Q33873297 |
| | Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 |
| | Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. | Q35606345 |
| | ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. | Q35936879 |
| | Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia | Q37676290 |
| | Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle | Q37979956 |
| | Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children | Q40518805 |
| | Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry | Q48125822 |
| | Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. | Q51026411 |
| | Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. | Q52575475 |
| | Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia. | Q53803392 |
| | Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. | Q54295812 |
| | Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay | Q73597507 |
| | Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia | Q83212219 |
| P433 | issue | 4 | |
| P921 | main subject | lymphoblastic leukemia | Q18553852 |
| P304 | page(s) | 223-229 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Pediatric Investigation | Q73542391 |
| P1476 | title | Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL-AML1 fusion transcript as a marker | |
| P478 | volume | 2 | |